Please contact us for more information or to learn if you are eligible to participate.
The primary objective is to extend the period for safety observation and collection of blood samples for up to 48 weeks after the last dose of aldafermin from subjects with non-cirrhotic NASH who have participated in Study18-0108 (Phase 2b, ALPINE 2/3).
Jose L. Almeda, MD
NGM Biopharmaceuticals, Inc.
Type of Trial